国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
5期
661-663
,共3页
盐酸氨溴索%肺表面活性物质%新生儿呼吸窘迫综合征
鹽痠氨溴索%肺錶麵活性物質%新生兒呼吸窘迫綜閤徵
염산안추색%폐표면활성물질%신생인호흡군박종합정
Ambroxol hydrochloride%Pulmonary surfactant%Neonatal respiratory distress syndrome
目的 研究盐酸氨溴索联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床效果.方法 将我院2007年5月至2011年9月收治的128例新生儿呼吸窘迫综合征的患儿随机分为两组,对照组64例患儿使用肺表面活性物质治疗,治疗组64例患儿加用盐酸氨溴索治疗,比较两组治疗情况.结果 对照组患儿肺表面活性物质使用剂量为(198.5±49.3)mg、机械通气时间为(78.4±18.4)h、住院时间为(18.5±5.6)d、并发症发生率为31.3%、病死率为10.9%,治疗组患儿肺表面活性物质使用剂量为(134.1±33.6)mg、机械通气时间为(56.1±11.9)h、住院时间为(11.2±3.8)d、并发症发生率为12.5%、病死率为1.6%,两组比较差异有统计学意义(P<0.05).结论 采用盐酸氨溴索联合肺表面活性物质治疗新生儿呼吸窘迫综合征效果令人满意,值得临床上推广应用.
目的 研究鹽痠氨溴索聯閤肺錶麵活性物質治療新生兒呼吸窘迫綜閤徵的臨床效果.方法 將我院2007年5月至2011年9月收治的128例新生兒呼吸窘迫綜閤徵的患兒隨機分為兩組,對照組64例患兒使用肺錶麵活性物質治療,治療組64例患兒加用鹽痠氨溴索治療,比較兩組治療情況.結果 對照組患兒肺錶麵活性物質使用劑量為(198.5±49.3)mg、機械通氣時間為(78.4±18.4)h、住院時間為(18.5±5.6)d、併髮癥髮生率為31.3%、病死率為10.9%,治療組患兒肺錶麵活性物質使用劑量為(134.1±33.6)mg、機械通氣時間為(56.1±11.9)h、住院時間為(11.2±3.8)d、併髮癥髮生率為12.5%、病死率為1.6%,兩組比較差異有統計學意義(P<0.05).結論 採用鹽痠氨溴索聯閤肺錶麵活性物質治療新生兒呼吸窘迫綜閤徵效果令人滿意,值得臨床上推廣應用.
목적 연구염산안추색연합폐표면활성물질치료신생인호흡군박종합정적림상효과.방법 장아원2007년5월지2011년9월수치적128례신생인호흡군박종합정적환인수궤분위량조,대조조64례환인사용폐표면활성물질치료,치료조64례환인가용염산안추색치료,비교량조치료정황.결과 대조조환인폐표면활성물질사용제량위(198.5±49.3)mg、궤계통기시간위(78.4±18.4)h、주원시간위(18.5±5.6)d、병발증발생솔위31.3%、병사솔위10.9%,치료조환인폐표면활성물질사용제량위(134.1±33.6)mg、궤계통기시간위(56.1±11.9)h、주원시간위(11.2±3.8)d、병발증발생솔위12.5%、병사솔위1.6%,량조비교차이유통계학의의(P<0.05).결론 채용염산안추색연합폐표면활성물질치료신생인호흡군박종합정효과령인만의,치득림상상추엄응용.
Objective To explore the clinical efficacy of ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome (NRDS).Methods 128 pediatric patients with NRDS who had been hospitalized during the period of May 2007 to September 2011 were randomly divided into two groups.The control group (64 patients) received therapy with pulmonary surfactant,while the study group (64 patients) received additional ambroxol hydrochloride.The efficacy was compared between the two groups.Resuts The dose of pulmonary surfactant uses was (198.5 ± 49.3)mg,duration of mechanical ventilation was (78.4 ± 18.4)h,length of hospital stay was (18.5 ± 5.6)d,rate of complications was 31.3%,and mortality rate was 10.9% in the control group; while the dose of pulmonary surfactant uses was (134.1 ± 33.6)mg,duration of mechanical ventilation was (56.1 ± 11.9)h,length of hospital stay was (11.2 ± 3.8)d,rate of complications was 12.5%,and mortality rate was 1.6% in the study group,with significant differences (P<0.05).Conclusions Ambroxol hydrochloride combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome is satisfactory and it is worth popularizing clinically.